Candel Therapeutics Appoints Martine Zimmermann to Board of Directors
Candel Therapeutics, Inc. announced the appointment of Martine Zimmermann, Pharm.D., to its Board of Directors, effective September 8, 2026. This appointment increases the board size from ten to eleven directors. Dr. Zimmermann, who qualifies as an independent director, will receive an option to purchase 64,000 shares of the Company's common stock and an annual retainer of $40,000. Her extensive experience in regulatory affairs and quality within the biopharmaceutical industry is expected to strengthen the board as Candel advances toward its planned Biologics License Application (BLA) submission for aglatimagene besadenovec.
Key Highlights
- Candel Therapeutics appointed Martine Zimmermann to its Board of Directors, increasing the board size to eleven.
- Dr. Zimmermann will receive an option to purchase 64,000 shares of common stock, vesting over three years.
- She will also receive a $40,000 annual retainer for her board service, paid quarterly.
- Dr. Zimmermann brings over 30 years of global regulatory affairs and quality expertise to the board.
- Her appointment is effective September 8, 2026, with her term expiring at the 2027 Annual Meeting of Stockholders.
Price Impact
More from CADL
Candel Therapeutics Q2 Net Loss $38.9M; Raises $117.7M Capital
Candel Therapeutics Q2 Net Loss $38.9M; Plans Aglatimagene BLA Q4 2026
Candel Therapeutics Q2 Net Loss $38.9M; BLA Planned Q4 2026; Cash to Q1 2028